Eli Lilly Facilitates the Withdrawal of Lartruvo (olaratumab) from the Global Market for Advanced Soft Tissue Sarcoma

Shots:

• The withdrawal follows the failure of P-III ANNOUNCE study assessing Lartruvo (olaratumab) + doxorubicin followed by Lartruvo as monothx vs doxorubicin + PBO followed by PBO in patients with advanced or metastatic STS, resulted with no improvement in survival of patients
• Lilly to establish a program ensuring current patients access to Lartruvo with limited interruption post withdrawal, agrees to continue in consultation with physician and knowing results of the ANNOUNCE study subject to local regulations, without enrolling any new patient in trial
• Lartruvo (olaratumab) is an Ab targeting PDGFR-α preventing the activation of the receptor possessing in-vitro and in-vivo anti-tumor activity against sarcoma cell lines and disrupted the PDGFR-α signaling pathway in in-vivo tumors

Click here to read full press release/ article | Ref: Eli Lilly | Image: OMC Technologies